Printer Friendly


Bio-Path Holdings, Inc. a biotechnology company developing a liposomal delivery technology for nucleic acid cancer drugs, has reported operational and financial results for the year 2012.

Enrollment continues in the Phase I clinical trial of Bio-Path's lead antisense cancer drug product Liposomal Grb-2 (BP-100-1.01). To date, the Company has successfully completed the first four cohorts of the study and treatment of patients in the fifth cohort is currently underway at The University of Texas MD Anderson Cancer Center. The drug has been well tolerated and possible anti-leukemia has been demonstrated. Through four cohorts, a total of 27 patients have been enrolled in the study, of which 15 have been evaluable. Liposomal Grb-2 is a novel, systemic liposomal antisense treatment for blood cancers. Patients eligible for enrollment have refractory or relapsed Acute Myeloid Leukemia (AML), Philadelphia Chromosome Positive Chronic Myelogenous Leukemia (CML), Acute Lymphoblastic Leukemia (ALL), or Myelodysplastic Syndrome (MDS) and have failed other approved treatments.

The ongoing Phase I clinical trial is a dose-escalating study to determine the safety and tolerance of escalating doses of Liposomal Grb-2, as well as the optimal biologically active dose for further development. The trial seeks a total of 18 to 30 evaluable patients and will evaluate at least five doses of Liposomal Grb-2 in five cohorts. An evaluable patient is a patient who has been able to complete the four-week treatment cycle.

As previously reported, since the safety profile of Liposomal Grb-2 is quite favorable, the Company expanded the protocol for its Phase I clinical trial to evaluate higher doses of Liposomal Grb-2 than originally planned. The expanded protocol will continue at 50 percent increments, with the dose for Cohort 5 being 60 mg/m2 followed by a dose of 90 mg/m2 for Cohort 6. If advantageous, the Company can continue testing at a higher dose of 135 mg/m2 with 33 percent increments thereafter. To date, there has been no evidence of significant toxicity from treatment with Liposomal Grb- 2. This provides a significant opportunity for the Company to test higher doses in patients in order to find a dose that provides maximum potential benefit and duration of anti-leukemia effect. Importantly, it is noted that through the fourth cohort, a total of nine patients had stabilized, in the opinion of the principal investigator, and had received additional treatments with Liposomal Grb-2. The Company expects to complete the Phase I clinical trial in 2013.

The clinical trial is being conducted at The University of Texas MD Anderson Cancer Center (MD Anderson).

In 2012, the Company added suppliers for the Grb-2 drug substance and for the final drug in order to support increased dose levels being administered to patients in the Phase I trial, as well as to meet requirements for patients who were stabilized and remained on treatment with Liposomal Grb-2 for extended periods of time.

Bio-Path's common stock began trading on the OTCQX on June 1, 2012. OTCQX is the highest tier, premier trading platform for OTC companies, and Bio-Path has qualified for the OTCQX.

During the second quarter of 2012, the Company launched an all-new website providing more detailed and up-to- date information on Bio-Path, its technology, product pipeline and clinical trial advancements.

In the third quarter of 2012, the Company announced its development plans for Liposomal Grb-2 and that it expects to conduct three Phase II clinical trials of the salvage therapy in combination with current frontline therapy in three of the types of leukemias that are currently being evaluated in the Company's Phase I clinical trial. These indications include AML, CML and MDS. These clinical trials are expected to take place at four of the leading cancer centers in the U.S. in 2013. Jorge Cortes, MD, principal investigator for the Company's Phase I clinical trial, is expected to be the principal investigator for the Phase II clinical trials.

In the fourth quarter of 2012, Bio-Path expanded its Board of Directors from three to four members with the appointment of Michael Garrison to the Company's Board of Directors. Mr. Garrison, 43, is a principal and President of Body Sculpt International, LLC, which owns and operates plastic surgery clinics under the trade name Sono Bello. Prior to founding Body Sculpt International, Mr. Garrison spent 10 years in a variety of executive roles with Dell, Inc., most recently as Director of Marketing, Americas Small and Medium Business. Previously, Mr. Garrison held general management and corporate development positions with ITT Industries, an industrial manufacturer. Mr. Garrison holds a Master's degree in Business Administration from Harvard Business School and a Bachelor of Science in Mechanical Engineering from Purdue University.

Focusing on its longer-term pipeline, the Company announced it is initiating development of its lead cancer drug BP-100-1.01 (Liposomal Grb-2) to treat triple negative breast cancer (TNBC) and inflammatory breast cancer (IBC), two cancers characterized by formation of aggressive tumors and relatively high mortality rates. Bio-Path's plan is to develop Liposomal Grb-2 as a targeted therapy against TNBC and IBC. Treatment goals are two-pronged: the first being to develop Liposomal Grb-2 as a tumor reduction agent in combination with other approved drugs in preoperative settings, and the second is to develop Liposomal Grb-2 as a drug to treat and control or eliminate cancer metastasis in TNBC and IBC patients. Both of these treatment goals address high need situations for patients.

The developmental plan will be comprised of preclinical testing in cell lines to determine the inhibitory effects of Liposomal Grb-2 on cell growth and invasion followed by preclinical studies in TNBC and IBC animal models. If the preclinical studies confirm benefit, Bio-Path anticipates that it would then proceed to a Phase I clinical trial. The preclinical programs are expected to start in 2013.

During 2012, Bio-Path continued to increase its profile and presented at three industry. The Company also participated in two retail investor conferences. These conferences are part of the Company's ongoing initiative to increase its visibility among investors.

In 2012, Bio-Path received $1.8 million in gross proceeds through the sale of shares of the Company's common stock. Subsequently, in the first quarter of 2013 the Company raised an additional $2 million in cash from the sale of common stock to accredited investors.

Financial Highlights

Net loss for the year 2012 was $(2,582,537), compared to a net loss of $(2,363,344) for the year 2011. The increase in net loss was due to an increase of $535,910 in research and development expense, primarily due to an approximate $500,000 increase in expense for drug product material used in the Company's clinical trial, in addition to increased expense for clinical trial operations and advisory services. The increase in research and development expense more than offset a decrease of $80,130 in related party research and development and a lower general and administrative expense of $238,716, which resulted primarily from a $320,000 decrease in administrative and management stock option expense, offset to some extent by increased expenses associated with being a public company and travel expenses and fees related to participation in industry conferences and meetings. For the full year 2012, the Company reported a net loss per share of $(0.04) based on 59,317,779 weighted average shares outstanding, compared to $(0.04) per share for the year 2011.

Operating expenses of $2,582,679 for the year 2012 increased by $217,064 compared to the year 2011, primarily due to increased drug material expense, offset to some extent, by reduced general and administrative expenses for management stock options.

As of December 31, 2012, the Company had cash of $534,046, compared to $952,252 at December 31, 2011. Net cash used in operating activities for the year 2012 was $(1,993,404) compared to $(1,149,911) for the year 2011. The primary reasons for the increase in net cash used in operations for the year over year period is the increased cash cost of clinical trial operations, including drug material, as well as receipt in 2011 of a $244,479 U.S. Government grant that was not matched in 2012. As previously noted, the Company raised an additional $2 million during the first quarter of 2013.

About Bio-Path's Delivery Technology

Bio-Path's drug delivery technology involves microscopic- sized liposome particles that distribute nucleic acid drugs systemically and safely throughout the human body, via simple intravenous infusion. The delivery technology is applied to single stranded (antisense) nucleic acid compounds with the potential to revolutionize the treatment of cancer and other diseases where drugable targets of disease are well characterized. About Growth Receptor Bound protein-2 (Grb-2)

The adaptor protein Growth Receptor Bound protein-2 (Grb-2) is essential to cancer cell signaling because it is utilized by oncogenic tyrosine kinases to induce cancer progression. Suppressing the function or expression of Grb-2 should interrupt its vital signaling function and have a therapeutic application in cancer. BP-100-1.01 is a neutral-charge, liposome-incorporated antisense drug substance designed to inhibit Grb-2 expression.

About Bio-Path Holdings, Inc.

Bio-Path is a biotechnology company focused on developing therapeutic products utilizing its proprietary liposomal delivery technology designed to systemically distribute nucleic acid drugs throughout the human body with a simple intravenous transfusion. Bio-Path's lead product candidate, Liposomal Grb-2, is in a Phase I study for blood cancers. Bio-Path's second drug candidate, also a liposomal antisense drug, is ready for the clinic where it will be evaluated in lymphoma and solid tumors.

For more information, visit or call 832/971-6616.
COPYRIGHT 2013 Worldwide Videotex
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2013 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Biotech Financial Reports
Article Type:Financial report
Date:May 1, 2013

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters